Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 7/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 7/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | AGPAT2 | O15120 | 2/20 | 0.32 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.31 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.31 |
| ▸ | MCHR1 | Q99705 | 4/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16740101 | 0.87 | ROCK2 (0.32) | CYP11B1CYP11B2CYP19A1AGPAT2CYP3A4 | |
| SCHEMBL16540805 | 0.86 | CYP11B1 (0.32) | CYP11B1CYP11B2CYP19A1AGPAT2CYP3A4 | |
| SCHEMBL18094395 | 0.83 | SCN9A (0.34) | CYP11B1CYP11B2CYP19A1CYP3A4MCHR1 | |
| SCHEMBL16740061 | 0.82 | CYP11B2 (0.38) | CYP11B1CYP11B2CYP19A1CYP3A4MCHR1 | |
| SCHEMBL16740289 | 0.82 | CYP11B2 (0.39) | CYP11B1CYP11B2CYP19A1CYP3A4ROCK2 | |
| SCHEMBL16740371 | 0.75 | ROCK1 (0.38) | CYP11B1CYP11B2CYP19A1AGPAT2MCHR1 | |
| SCHEMBL15742382 | 0.74 | ROCK1 (0.40) | AGPAT2 | |
| SCHEMBL16747893 | 0.74 | AGPAT2 (0.36) | AGPAT2ABCB1ABCC1ABCG2CYP3A4 | |
| SCHEMBL15742791 | 0.71 | BMI1 (0.49) | ROCK2 | |
| SCHEMBL16740324 | 0.71 | CYP11B2 (0.41) | CYP11B1CYP11B2CYP19A1MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180483-B2 | Substituted reverse pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | claimed |
| EP-2922828-B1 | 4,6-DIAMINO-PYRIMIDINE DERIVATIVES AS BMI-1 INHIBITORS FOR TREATING CANCER | PTC THERAPEUTICS INC (US) | 2020-07-08 | — | — | EP | claimed |
| US-10428050-B2 | Substituted reverse pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | claimed |
| US-20150315182-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2015-11-05 | — | — | US | claimed |
| US-20220064150-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS INC (US) | 2022-03-03 | — | — | US | disclosed |
| US-20220064150-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS INC (US) | 2022-03-03 | — | — | US | disclosed |
| US-11180483-B2 | Substituted reverse pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11180483-B2 | Substituted reverse pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2021-11-23 | — | — | US | disclosed |
| EP-2922828-B1 | 4,6-DIAMINO-PYRIMIDINE DERIVATIVES AS BMI-1 INHIBITORS FOR TREATING CANCER | PTC THERAPEUTICS INC (US) | 2020-07-08 | — | — | EP | disclosed |
| EP-2922828-B1 | 4,6-DIAMINO-PYRIMIDINE DERIVATIVES AS BMI-1 INHIBITORS FOR TREATING CANCER | PTC THERAPEUTICS INC (US) | 2020-07-08 | — | — | EP | disclosed |
| US-10428050-B2 | Substituted reverse pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428050-B2 | Substituted reverse pyrimidine Bmi-1 inhibitors | PTC THERAPEUTICS, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20150315182-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315182-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2015-11-05 | — | — | US | disclosed |
| US-20150315182-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. | 2015-11-05 | — | — | US | disclosed |
| WO-2014081906-A2 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | PTC THERAPEUTICS, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180483-B2 | Substituted reverse pyrimidine Bmi-1 inhibitors | BMI1, BRPF3, BAZ2A | CYP11B1 4314/4885CYP11B2 4696/4885CYP19A1 4016/4885 |
| US-20150315182-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | BMI1, BRPF3, BAZ2A | CYP11B1 4314/4885CYP11B2 4696/4885CYP19A1 4016/4885 |
| US-10428050-B2 | Substituted reverse pyrimidine Bmi-1 inhibitors | BMI1, BRPF3, BAZ2A | CYP11B1 4314/4885CYP11B2 4696/4885CYP19A1 4016/4885 |
| US-20220064150-A1 | SUBSTITUTED REVERSE PYRIMIDINE BMI-1 INHIBITORS | BMI1, BRPF3, BAZ2A | CYP11B1 4314/4885CYP11B2 4696/4885CYP19A1 4016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.